European Vaccine Initiative: Lessons from developing malaria vaccines

Expert Review of Vaccines

Volumn 10, Issue 12, 2011, Pages 1697-1708

  Geels, Mark J ^a   Imoukhuede, Egeruan B ^a   Imbault, Nathalie ^a   Van Schooten, Harry ^a   McWade, Terry ^b   Troye Blomberg, Marita ^c   Dobbelaer, Roland ^d   Craig, Alister G ^e   Leroy, Odile ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d Liverpool School of Tropical Medicine ^*  (Belgium)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

diseases of poverty; EMVI; EVI; malaria; PDP; research infrastructure; vaccine

Indexed keywords

ADENOVIRUS VECTOR; AMA1 DICO VACCINE; APICAL MEMBRANE ANTIGEN 1; JAIVAC 1 VACCINE; MALARIA VACCINE; MSP3 VACCINE; P27A VACCINE; POLYPROTEIN; RECOMBINANT GMZ2; UNCLASSIFIED DRUG;

DRUG ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EUROPE; FUNDING; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HUMAN; MALARIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TROPICAL DISEASE; VACCINATION;

EID: 81355147426     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.158     Document Type: Review

References (44)

1. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373(9674), 1570-1575 (2009).
2. Breman JG, Egan A, Keusch GT. The intolerable burden of malaria: a new look at the numbers. Am. J. Trop. Med. Hyg. 64(Suppl. 1-2), iv-vii (2001).
3. Roca-Feltrer A, Carneiro I, Armstrong Schellenberg JR. Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years. Trop. Med. Int. Health 13(6), 771-783 (2008). (Pubitemid 351678643)
4. Thwing J, Eisele TP, Steketee RW. Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the lives saved tool. BMC Pub. Health 11(Suppl. 3), S14 (2011).
5. O'Meara WP, Bejon P, Mwangi TW et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372(9649), 1555-1562 (2008).
6. A research agenda for malaria eradication: vaccines. PLoS Med. 8(1), e1000398 (2011).
7. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized controlled trial. Lancet 366(9502), 2012-2018 (2005). (Pubitemid 41773376)
8. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccines 6(1), 90-96 (2010).
9. Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev. Vaccines 10(5), 589-599 (2011).
10. Greenwood B, Targett G. The mysteries of immunity to malaria. Lancet 377(9779), 1729-1730 (2011).
11. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120(12), 4168-4178 (2010).
12. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin. Microbiol. Rev. 22(1), 13-36 (2009).
13. Imoukhuede EB, Ventura R, Imbault N, Van Schooten H, Leroy O. European Malaria vaccine initiative: portfolio and perspectives for the future. Hum. Vaccin. 6(1), 146-150 (2009).
14. Roestenberg M, Remarque E, De Jonge E et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One3(12), e3960 (2008).
15. Osier FH, Weedall GD, Verra F et al. Allelic diversity and naturally acquired allelespecific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect. Immun. 78(11), 4625-4633 (2010).
16. Ouattara A, Mu J, Takala-Harrison S et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar. J. 9, 175 (2010).
17. Theisen M, Soe S, Brunstedt K et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 22(9-10), 1188-1198 (2004). (Pubitemid 38296662)
18. Esen M, Kremsner PG, Schleucher R et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 27(49), 6862-6868 (2009).
19. Mordmuller B, Szywon K, Greutelaers B et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine 28(41), 6698-6703 (2010).
20. Porter DW TF, Berthoud TK, Hutchings CL et al. A human Phase 1/2a malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29(43), 7514-7522 (2011).
21. Olugbile S, Habel C, Servis C, Spertini F, Verdini A, Corradin G. Malaria vaccines - the long synthetic peptide approach: technical and conceptual advancements. Curr. Opin. Mol. Ther. 12(1), 64-76 (2010).
22. Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 365(11), 1062-1064 (2011).
23. Sirima SB, Tiono AB, Ouedraogo A et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One 4(10), e7549 (2009).
24. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24(2), 74-84 (2008).
25. Craig AG, Holder AA, Leroy OY, Ventura RA. Malaria vaccines - how and when to proceed? Trends Parasitol. 25(12), 535-537 (2009).
26. Villard V, Agak GW, Frank G et al. Rapid identification of malaria vaccine candidates based on a-helical coiled coil protein motif. PLoS One 2(7), e645 (2007).
27. Olugbile S, Villard V, Bertholet S et al. Malaria vaccine candidate: design of a multivalent subunit a-helical coiled coil poly-epitope. Vaccine 29(40), 7090-7099 (2011).
28. Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25(5), 806-813 (2007). (Pubitemid 44856130)
29. Richards JS, Stanisic DI, Fowkes FJ et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51(8), e50-e60 (2010).
30. Hill AV, Reyes-Sandoval A, O'Hara G et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6(1), 78-83 (2010).
31. Reyes-Sandoval A, Sridhar S, Berthoud T et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38(3), 732-741 (2008).
32. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 8, 312 (2009).
33. Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondinrelated adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74(10), 5933-5942 (2006) (Pubitemid 44484581)
34. Sheehy SH, Duncan CJ, Elias SC et al. Phase 1a clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. doi:10.1038/mt.2011.176 (2011) (Epub ahead of print).
35. O'Hara GA, Duncan CJA, Ewer KJ et al. Clinical assessment of a recombinant simian adenovirus chad63: a potent new vaccine vector. J. Infect. Dis. (2011) (In Press).
36. Moorthy VS, Kieny MP. Reducing empiricism in malaria vaccine design. Lancet Infect. Dis. 10(3), 204-211 (2010).
37. Cavanagh DR, Dubois PM, Holtel A et al. Towards validated assays for key immunological outcomes in malaria vaccine development. Vaccine 29(17), 3093-3095 (2011).
38. Kisser A, Heininger U, Moorthy VS, Akanmori BD, Leroy O. Addressing the needs and gaps in safety assessment of vaccines during clinical trials in resource limited countries. Vaccine 29(24), 4173-4174 (2011).
39. Thogersen RL, Holder AA, Hill AV, Arnot DE, Imoukhuede EB, Leroy O. Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field? Malar. J. 10(1), 255 (2011).
40. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11(2), 102-109 (2011).
41. Roestenberg M, Mccall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361(5), 468-477 (2009).
42. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433(7022), 164-167 (2005).
43. + T cell immunity. Science 334(6055), 475-480 (2011).
44. Vaughan AM, Wang R, Kappe SH. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccin. 6(1), 107-113 (2010).